Strauss D
Folia Haematol Int Mag Klin Morphol Blutforsch. 1978;105(3):407-19.
Haemotherapy developed in the direction of transfusing pure blood cell preparations, if possible and enlarging the therapy with plasma fraction considerably. Quality losses of haemotherapeutics will already occur when they are prepared. This is mainly due to the conditions of blood collecting, blood stabiliser, duration and storage temperature from the blood collecting to further processing as well as biological variability of the composition of the donor's blood. The amount of substrate available to erythrocytes differs in various blood stabilisers. Deplasmatized erythrocyte concentrates can be used after several weeks of storage, if a high glucose concentration is present in the blood stabiliser. In CPD media the function of erythrocytes, the oxygen supply of the tissue, will remain intact a week longer than in ACD media. This effect will be increased by xylitol and pyruvate as well as by adding bicarbonate simultaneously. In future a primary importance will have to be attached to an improved storage of erythrocytes in the form of resuspended buffy coat-free erythrocyte concentrates.
血液疗法朝着输注纯血细胞制剂的方向发展，如有可能，还会大幅扩大血浆成分的治疗应用。血液治疗剂在制备过程中就会出现质量损失。这主要归因于采血条件、血液稳定剂、从采血到进一步加工的持续时间和储存温度，以及献血者血液成分的生物变异性。不同的血液稳定剂中，红细胞可利用的底物量有所不同。如果血液稳定剂中存在高浓度葡萄糖，去血浆红细胞浓缩液在储存几周后仍可使用。在CPD培养基中，红细胞的功能，即组织的氧气供应，比在ACD培养基中能保持完整一周的时间。木糖醇、丙酮酸以及同时添加碳酸氢盐会增强这种效果。未来，必须高度重视以重悬的无白膜层红细胞浓缩液的形式改善红细胞的储存。
